Purchase Order 75F40125P00252
Award Date 9/18/25
Potential Completion Date 10/20/25
Potential Value $97K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration awarded a firm fixed price purchase order valued at $534,536 to Illumina, Inc., a San Diego-based biotechnology company specializing in genomic sequencing technologies, for one Illumina NextSeq 2000 Sequencer with post-warranty correction and remedial repair services. The contract, awarded on August 17, 2023, with an ultimate completion date of December 11, 2028, was issued under a combined synopsis/solicitation posted in May 2023. The sequencer will be delivered...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
- This is a firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based analytical instruments and reagents for genetic and genomic analysis. The contract is for the provision of a MiSeq sequencing instrument to support the FDA's genomic sequencing and analysis work, with a ceiling value of $81,810. The contract is not associated with a set-aside or a larger contract vehicle, and there is no indication of any...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of the MiSeq whole genome sequencing instrument, a genome sequencer, with a ceiling value of $166,207.78 and a period of performance through June 30, 2029. The contract is not set aside for any specific business designation. Illumina holds multiple federal...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and related products, for the provision of a MiSeq sequencing instrument and a one-year preventative maintenance agreement. The total potential value of this contract is $109,857.00. Illumina has a history of providing sequencing systems and services to support genomic research and diagnostics across various federal...
- The Food and Drug Administration awarded a $233.7K firm fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 Sequencing System plus one option year of post-warranty maintenance. The award was issued on June 17, 2024, with an ultimate completion date of July 23, 2026. The equipment will be delivered to and maintained at the FDA's National Center for Toxicological Research in Jefferson, Arkansas, though the place of performance is listed as Singapore. No set-aside...
- The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The $114,681.00 contract is for the delivery of a MiSeq System, a high-throughput next-generation DNA sequencing platform used to support life science research, applied markets, and molecular diagnostics. This award does not have a set-aside designation. Illumina has a history of providing...
- This firm fixed price delivery order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $81,810 contract is for the provision of a MiSeq instrument, with no set-aside designation. Illumina has a history of providing sequencing systems, reagents, and bioinformatics support to various federal agencies for research and diagnostic applications. This order falls under Illumina's $3.3...